Language: BG BG
← Back to results
Recruiting Phase 4 2025-524311-37-00

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margar

Phase 4 – monitoring after market approval
Conditions: chronic myeloid leukemia Philadelphia chromosome-positive acute lymphoblastic leukemia

Sponsor: Sun Pharmaceutical Industries Limited

trial.available_in: БГ
Overview
Trial status: Authorised
Who can participate
Age group: 18-64 years Gender: Male Target enrollment: 56 participants
Locations 1
Romania (1)
Technical details
Status
Recruiting
Phase
Phase 4
Study type
INTERVENTIONAL
Sex
Male only
Minimum age
18 Years
Maximum age
64 Years
Healthy volunteers
No
Start date
20.04.2026
Registry ID
2025-524311-37-00
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.